Keros Therapeutics Inc. (KROS)
NASDAQ: KROSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KROS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $217.44M
- EPS (TTM)
- -$2.32
- Dividend yield
- None
- 52-week range
- 8.98 – 22.55
- Day range
- 11.04 – 11.59
- Volume / Avg
- 208.69K / 196.50K
- Beta
- —
- Shares outstanding
- 19.62M
52-week range
KROS stock today
Shares of Keros Therapeutics (KROS) finished lower on Nov 20 at $11.08, a drop of 2.72% or $0.31 per share, versus the S&P 500's 3.70% decline. Shares are 50.9% below their 52-week high of $22.55, set on Dec 8, 2025 and 23.4% above the 52-week low of $8.98, near the bottom of the past year's range. KROS is down 45.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.3%.
Keros Therapeutics has posted a net loss over the last twelve months (EPS of -$2.32), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Keros Therapeutics
Company profileKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jasbir S. Seehra Ph.D.
- Headquarters
- Lexington, MA
- Employees
- 87
- IPO year
- 2020
- Website
- kerostx.com
Financial highlights
Full financialsIn fiscal 2025, Keros Therapeutics generated $243.9 million in revenue, up 0.0% from fiscal 2024. Net income was $87.0 million, for a net margin of 35.7% versus a median of -50805.7% in the prior 5 years. Operating margin was 27.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $243.86M | $0 | $151.00K | $0 | $20.10M |
| Growth | — | -100.00% | — | -100.00% | — |
| Net income | $87.01M | $-187.35M | $-152.99M | $-104.68M | $-58.74M |
| EPS (diluted) | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 |
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$19.83+78.97%
- Strong buy 0
- Buy 4
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.70 vs $-0.96
- Surprise
- +172.92%
KROS news
All KROS news- Best Momentum Stocks to Buy for November 19thNasdaqAGL, AIZ, KROS
- New Strong Buy Stocks for November 19thNasdaqAGL, AIZ, PANL, EQNR
- Keros Therapeutics Launches $5 Mln Buyback Following Takeda Milestone PaymentNasdaqKROS, LEN.B
- Keros Therapeutics Authorizes Additional $5 Mln Share Repurchase ProgramNasdaq
- Keros Therapeutics, Inc. Announces $5 million Share Repurchase Program Following $20 million MilestoneNasdaqKROS, ET
- Keros Therapeutics Announces Additional $5 Million Share Repurchase AuthorizationGlobeNewswire
- Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HSNasdaqNVS, COLL, VCEL, KROS
- Keros Therapeutics, Inc. Reports Third Quarter 2026 Financial ResultsNasdaq
Keros Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RCKTRocket Pharmaceuticals Inc. | 1.95 | -7.58% | $217.74M | vs KROS |
| PYXSPyxis Oncology Inc. | 1.81 | +7.74% | $216.49M | vs KROS |
| IMRXImmuneering Corporation Class A | 3.38 | -2.03% | $218.90M | vs KROS |
| ARCTArcturus Therapeutics Holdings Inc. | 7.45 | -1.97% | $214.73M | vs KROS |
| ENTAEnanta Pharmaceuticals Inc. | 7.62 | -4.51% | $222.19M | vs KROS |
| CYPHCypherpunk Technologies Inc. | 1.41 | -18.02% | $210.15M | vs KROS |
| VNDAVanda Pharmaceuticals Inc. | 3.45 | -6.13% | $208.32M | vs KROS |
| FTHFaeth Therapeutics Inc. | 7.88 | -9.32% | $203.65M | vs KROS |
Indexes, lists and sector
Keros Therapeutics stock FAQ
What is Keros Therapeutics's stock price today?
KROS last traded at $11.08 as of Nov 20, 4:00 PM EST, down 2.72% on the day. Prices are delayed at least 15 minutes.
Who is Keros Therapeutics's CEO?
Dr. Jasbir S. Seehra Ph.D. is the chief executive officer of Keros Therapeutics Inc., which has about 87 employees.
What is the KROS 52-week high?
The 52-week high for KROS is $22.55 and the 52-week low is $8.98. The stock is currently 50.9% below its high.